You are here

priority review vouchers

Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approved

Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approved

Reuters

priority review vouchers

sickle cell disease

Flag link:

Sarepta sells FDA priority review voucher to mystery buyer for $102M as prices continue to slip

Sarepta sells FDA priority review voucher to mystery buyer for $102M as prices continue to slip

Fierce Pharma

Sarepta Therapeutics

priority review vouchers

Flag link:

Novartis buys priority review voucher from Pharming for discount price of $21M

Novartis buys priority review voucher from Pharming for discount price of $21M

Fierce Biotech

priority review vouchers

Flag link:

Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position

Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position

Benzinga

priority review vouchers

Flag link:

European pharma group wants to create PRV-like system to spur antibiotics R&D

European pharma group wants to create PRV-like system to spur antibiotics R&D

Endpoints

priority review vouchers

Flag link:

Marinus Pharma Shares Up After Deal for Rare Pediatric Disease Priority Review Voucher

Marinus Pharma Shares Up After Deal for Rare Pediatric Disease Priority Review Voucher

Morningstar

Marinus Pharmaceuticals

priority review vouchers

Flag link:

AbbVie Redeems Priority Review Voucher for Rinvoq Approval

AbbVie Redeems Priority Review Voucher for Rinvoq Approval

BioSpace

priority review

priority review vouchers

ulcerative colitis

Flag link:

BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal

BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal

Fierce Biotech

priority review vouchers

Flag link:

Newly acquired Alexion pays $100M for Rhythm's speedy review voucher

Newly acquired Alexion pays $100M for Rhythm's speedy review voucher

Fierce Biotech

priority review vouchers

Flag link:

Vifor buys priority review voucher for undisclosed filing

Vifor buys priority review voucher for undisclosed filing

Fierce Biotech

priority review vouchers

priority review

Flag link:

Fees for Redeeming Priority Review Vouchers Fall to All-Time Low in FY2020

Fees for Redeeming Priority Review Vouchers Fall to All-Time Low in FY2020

RAPS.org

priority review vouchers

Flag link:

AstraZeneca pays Sobi $95M for priority review voucher

AstraZeneca pays Sobi $95M for priority review voucher

Fierce Biotech

priority review vouchers

Flag link:

Everything Old is New Again: FDA Revises its 2014 Rare Pediatric Disease Priority Review Voucher Guidance for Industry

Everything Old is New Again: FDA Revises its 2014 Rare Pediatric Disease Priority Review Voucher Guidance for Industry

FDA Law Blog

priority review

priority review vouchers

Flag link:

Priority Review Vouchers And Access To Drugs Targeting Neglected Diseases

Priority Review Vouchers And Access To Drugs Targeting Neglected Diseases

Forbes

priority review vouchers

Flag link:

Rare pediatric PRV program not linked to uptick in new drugs starting trials, study finds

Rare pediatric PRV program not linked to uptick in new drugs starting trials, study finds

Forbes

clinical trials

priority review vouchers

pediatric rare diseases

Flag link:

Priority Review Vouchers Revitalizing Neglected Disease Drug Development

Priority Review Vouchers Revitalizing Neglected Disease Drug Development

Forbes

neglected tropical diseases

tropical diseases

priority review vouchers

Flag link:

Lilly buys Siga's Priority Review voucher gained via smallpox approval

Lilly buys Siga's Priority Review voucher gained via smallpox approval

BioCentury

SIGA technologies

priority review vouchers

Flag link:

FDA adds four tropical diseases to Priority Review voucher program

FDA adds four tropical diseases to Priority Review voucher program

BioCentury

priority review vouchers

tropical diseases

chikungunya virus

cryptococcal meningitis

Flag link:

Sparks sells regulatory fast pass to Jazz for $110M

Sparks sells regulatory fast pass to Jazz for $110M

Biopharma Dive

Spark Therapeutics

Jazz Pharmaceuticals

priority review vouchers

Flag link:

Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease

Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease

CP Wire

Abeona Therapeutics

Rare Pediatric Disease designation

priority review vouchers

Flag link:

Pages